Official (ISC)2 Study Guide for the Information System Security Engineering Professional (ISSEP) Exam

Official (ISC)2 Study Guide for the Information System Security Engineering Professional (ISSEP) Exam

Official (ISC)2(R) Guide to the CISSP-ISSEP(R) CBK(R) provides an inclusive analysis of all of the topics covered on the newly created ISSEP Exam. The first fully comprehensive guide to the test, it promotes understanding of the four ISSEP domains. It explains ISSE by comparing it to a traditional Systems Engineering model, enabling readers to see the correlation of how security fits into the design and development process. It also details key points of more than 50 U.S. government policies and procedures, which need to be understood in order to gain ISSEP certification. According to Jim Wiggins of SAIT/IMT who used the book to pass the test, which is typically passed by only 30 percent of applicants, “I’d say you’ve done a pretty good job in writing a book that helps prepare candidates for the test as well as provide them a great resource for understanding much of the process of the Federal Government relating to IA…”

List Price: $ 69.95

Price:

Related Products

DCE-MRI Study Abstract Selected by ASCO

DCE-MRI Study Abstract Selected by ASCO
PHILADELPHIA—-ACR Image Metrix™ is pleased to announce that the DCE-MRI study, as commissioned by Bionomics Ltd., was submitted as an abstract by Bionomics to the American Society of Clinical Oncology and has been accepted to be presented as a part of the scientific program during the general poster session at the ASCO Annual Meeting, which will take place June 4-8, 2010, in Chicago, Illinois …

Read more on Business Wire via Yahoo! Finance

A case study on obstacles to the growth of biotechnology

Product Description
This digital document is a journal article from Technological Forecasting & Social Change, published by Elsevier in 2007. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.

Description:
Why has a biotechnology industry developed much faster in some countries than in others? Studies indicate that public funding for research is not sufficient for the establishment of a strong biotech industry. What should countries and regions do then, in order to become globally competitive in the area? In this paper I concentrate on the upstream section of biotech growth – the creation of new biotechnology companies – and take a closer look at the case of Portugal, a country where the industry has long been at an embryonic stage. It becomes apparent from the analysis that generalist, top-down measures to stimulate general technological development may not be appropriate to foster a sector composed of many unique characteristics. Evidence from several countries suggests that there is a group of specific factors which all have to be in place simultaneously to allow the emergence of a biotech industry. A careful analysis of the Portuguese example – when set against the background of European and Global biotech – may help regions such as southeast Asia and southern Europe define their paths to bio-competitiveness.

A case study on obstacles to the growth of biotechnology

Pharmacokinetics in Drug Development: Clinical Study Design and Analysis

Product Description

These volumes are designed to be the most complete guide to pharmacokinetics (PK) and its role in drug development. Geared toward graduate level students and scientists in the areas of clinical pharmacology and PK, the volumes will fill a gap between the academic science and the practical application of that knowledge in drug development. Volume 1 discusses the role that PK plays in selected clinical study designs, including first-time-in-man, biopharmaceuticals, and special population studies. Volume 2 details the key regulatory and development paradigms in which PK supplements decision-making during drug development.

Pharmacokinetics in Drug Development: Clinical Study Design and Analysis

Anti-cancer Rituxan cuts lymphoma recurrence in half: study

Anti-cancer Rituxan cuts lymphoma recurrence in half: study
Long-term treatment with anti-cancer medication Rituxan, produced by Swiss laboratory Roche, can cut the recurrence of follicular lymphoma in some patients by half, a new study said.

Read more on PhysOrg

Next Page »